Evidence map›Paper›PMID 40438187›Full record

ArticleInternational journal of nanomedicine2025

Functionalized Boron Carbide Nanoparticles as Active Boron Delivery Agents Dedicated to Boron Neutron Capture Therapy.

Anna Rudawska, Bożena Szermer-Olearnik, Agnieszka Szczygieł, Jagoda Mierzejewska, Katarzyna Węgierek-Ciura, Paulina Żeliszewska, Dawid Kozień, Monika Chaszczewska-Markowska, Zbigniew Adamczyk, Piotr Rusiniak and 4 more

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Boron in Diet and Medicine: Mechanisms of Delivery and Detection.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Anna RudawskaHirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.ORCID 0000-0001-8802-5859
Bożena Szermer-OlearnikHirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.ORCID 0000-0002-1451-4227
Agnieszka SzczygiełHirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.ORCID 0000-0003-1516-5636
Jagoda MierzejewskaHirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
Katarzyna Węgierek-CiuraHirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
Paulina ŻeliszewskaJerzy Haber Institute of Catalysis and Surface Chemistry, Polish Academy of Sciences, Krakow, Poland.
Dawid KozieńDepatment of Materials Science and Ceramics, AGH University of Krakow, Krakow, Poland.
Monika Chaszczewska-MarkowskaHirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
Zbigniew AdamczykJerzy Haber Institute of Catalysis and Surface Chemistry, Polish Academy of Sciences, Krakow, Poland.
Piotr RusiniakDepartment of Geology, Geophysics and Environmental Protection, AGH University of Krakow, Krakow, Poland.ORCID 0000-0001-6699-2282
Katarzyna WątorDepartment of Geology, Geophysics and Environmental Protection, AGH University of Krakow, Krakow, Poland.ORCID 0000-0002-1921-5146
Andrzej RapakHirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
Zbigniew PędzichDepatment of Materials Science and Ceramics, AGH University of Krakow, Krakow, Poland.
Elżbieta Pajtasz-PiaseckaHirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Boron neutron capture therapy (BNCT) is a promising targeted radiotherapy that enables the treatment of cancers at the cellular level. The crucial aspect of BNCT are boron carriers, which should selectively reach cancer cells by delivering high concentrations of boron. Therefore, we propose the use of boron carbide (B Methods: Hydrodynamic diameter measurements confirmed the stability of functionalized B Results: Functionalized B Conclusion: Stable complexes of antibody-functionalized B

Indexed as

BoronBoron CompoundsBoron Neutron Capture TherapyNanoparticlesCell Line, TumorCell SurvivalErbB ReceptorsHumansReceptors, LDLBoronBoron CompoundsEGFR protein, humanErbB ReceptorsReceptors, LDLanticancer therapyBNCTboron carbidenanoparticlestargeted functionalization

Identifiers

PMID40438187
PMCPMC12118811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.